Ser418
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser418  -  SMAD3 (human)

Site Information
LtQMGsPsIRCssVs   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 6845003

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry (in vitro) ( 1 ) , mutation of modification site ( 1 , 2 ) , phospho-antibody ( 1 , 2 ) , western blotting ( 1 , 2 )
Disease tissue studied:
liver cancer ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
CK1G2 (human) ( 1 )
Kinases, in vitro:
CK1G2 (human) ( 1 )
Treatments:
MG132 ( 1 ) , TGF-beta ( 1 )

Downstream Regulation
Effects of modification on SMAD3:
activity, inhibited ( 1 ) , intracellular localization ( 2 ) , protein degradation ( 1 ) , ubiquitination ( 1 )
Effects of modification on biological processes:
cell growth, inhibited ( 1 ) , signaling pathway regulation ( 1 )

References 

1

Guo X, et al. (2008) Ligand-dependent ubiquitination of Smad3 is regulated by casein kinase 1 gamma 2, an inhibitor of TGF-beta signaling. Oncogene 27, 7235-47
18794808   Curated Info

2

Chuderland D, Konson A, Seger R (2008) Identification and characterization of a general nuclear translocation signal in signaling proteins. Mol Cell 31, 850-61
18760948   Curated Info